5 results
Primary objectiveTo determine the feasibility of plerixafor 320 *g/kg subcutaneously to harvest a sufficient number of CD34+ peripheral blood stem cells/kg recipient body weight. Feasibilty is defined as a minimum of 2.0x10^6/kg CD34+ cells in oneā¦
In this study, plerixafor, the study drug, will be given in addition to GCSF to see if it works the same way in children as in adults.
The objective of the study is to test the effects of the p-glycoproteine transporter on cognitive test in healthy volunteers and to explore the effects of the p-glycoproteine transporter on functional Magnetic Resonance Imaging (fMRI).
To demonstrate that Plerixafor is able to reduce the need for invasive mechanical ventilation or death in severe COVID-19 patients admitted in Intensive Care Unit (ICU)
to determine the concentration of currently often used ARV (doravirine, raltegravir, bictegravir, tenofovir alafenamide, emtricitabine) in breast milk after administration of a single dose